|Bid||0.00 x 1400|
|Ask||0.00 x 1400|
|Day's Range||39.57 - 42.04|
|52 Week Range||21.56 - 53.70|
|Beta (5Y Monthly)||2.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 28, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.00|
Acadia (ACAD) delivered earnings and revenue surprises of 8.11% and 2.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2019.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on February 26, 2020, at 5:00 p.m. Eastern Time to discuss financial results and operations.
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the...
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session.
Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...